The aim of this guideline is to assist in raising standards of the delivery of radical treatments. The selection of patients for radical treatment requires an investigation pathway directed towards providing as much diagnostic and staging information as possible. Based on the retrospective and observational studies, radical management is the accepted as a standard.
The remainder of this section focuses on specific disease subgroups like T3, T4, N2, N3 and M1 diseases, bronchioloalveolar carcinoma, open and close thoracotomy etc. In this guideline, a tripartite risk assessment model is presented which gives details regarding the risks of operative mortality, perioperative myocardial events and postoperative dyspnoea along with surgical approach, chemotherapy and radical radiotherapy. It is recommended that in early stage disease where patients have significant comorbidities or poor lung…
